Publications

drug interactions (10 POSTS)

2024 (2 POSTS)

1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential

Xue Y, Wang L, Huo R, Chen M, Melo B, Dingley K, et al. 2024. 1β-Hydroxydeoxycholic acid as an endogenous biomarker in human plasma for assessment of CYP3A clinical drug-drug interaction potential. Drug Metab Dispos 52(9):966–974; doi: 10.1124/dmd.124.001680. PMID: 38991779.

View Abstract

Prospective application of physiologically based pharmacokinetic (PBPK) modeling to inform the design of a clinical drug-drug Interaction (DDI) study: Case study of mezigdomide

Burnett J, Sychterz C, Zhu D, Shakeel F, Dingley K, Chen W, et al. Prospective application of physiologically based pharmacokinetic (PBPK) modeling to inform the design of a clinical drug-drug interaction (DDI) study: Case study of mezigdomide. Poster presented at American Society of Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, Colorado Springs, CO, March 2024.

View Abstract

2022 (1 POST)

Vocacapsaicin (formerly CA-008): A water-soluble prodrug for rapid release of capsaicin for the treatment of postsurgical pain

Knotts T, Diokno R, Husfeld C, Weinberger D, Mease K, Wollowitz S, Kramer S, Donovan J. Vocacapsaicin (formerly CA-008): A water-soluble prodrug for rapid release of capsaicin for the treatment of postsurgical pain. Presentation to American Association of Pharmaceutical Scientists, AAPS PHARMSCI 360, Boston, MA, October 2022.

View Abstract

2021 (1 POST)

How many doses of an Ames-positive/mutagenic (DNA reactive) drug can be safely administered to healthy subjects?

Robison TW. How many doses of an Ames-positive/mutagenic (DNA reactive) drug can be safely administered to healthy subjects? Genetic Toxicology Association, 2021.

2020 (1 POST)

Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

View Abstract

2013 (1 POST)

Regulatory review of XELJANZ® (Tofacitinib) from the nonclinical perspective

Robison TW. Regulatory review of XELJANZ® (Tofacitinib) from the nonclinical perspective. American College of Toxicology Annual Meeting, 2013.

2007 (1 POST)

Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways

Urban JD, Vargas G, von Zastrow M, Mailman RB. 2007. Aripiprazole has functionally selective actions at D2 receptor-mediated signaling pathways. Neuropsychopharmacol 32(1):67-77; doi: 10.1038/sj.npp.1301071.

View Abstract

2004 (1 POST)

Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor?

Urban JD, Gay EA, Mailman RB. Decreased neurological side-effects with aripiprazole: A result of functional selectivity of the D2 receptor? Society of Toxicology 43rd Annual Meeting, Baltimore, MD, March 2004.

1998 (1 POST)

Isolation of partially purified P450 2D18 and characterization of activity towards the tricyclic antidepressants imipramine and desipramine

Thompson CM, Kawashima H, and Strobel HW. 1998. Isolation of partially purified P450 2D18 and characterization of activity towards the tricyclic antidepressants imipramine and desipramine. Arch Biochem Biophys 359(1):115–121; doi: 10.1006/abbi.1998.0892.

View Abstract

1994 (1 POST)

Adenosine A2 and PAT- σ3 agonists affect adenylyl cyclase activity and dopamine synthesis

Choksi NY, Hussain A, Owens CE, Myers AM, Harvey RD, Baldessarini RJ, Wyrick SD, Booth RG. Adenosine A2 and PAT- σ3 agonists affect adenylyl cyclase activity and dopamine synthesis. Poster presented at North Carolina Society for Neuroscience Meeting, 1994.